ponatinib for CML T315I
Selected indexed studies
- Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. (Am J Hematol, 2024) [PMID:39093014]
- Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. (Am J Hematol, 2022) [PMID:35751859]
- Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. (N Engl J Med, 2019) [PMID:31826340]
_Worker-drafted node — pending editorial review._
Connections
ponatinib for CML T315I is a side effect of
Sources
- Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. (2019) pubmed
- Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. (2024) pubmed
- Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. (2022) pubmed
- Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. (2020) pubmed
- Management of chronic myeloid leukemia in 2023 - common ground and common sense. (2023) pubmed
- Ponatinib for CML patients in routine clinical practice: the PONDEROSA study. (2026) pubmed
- Ponatinib: a third-generation inhibitor for the treatment of CML. (2014) pubmed
- Ponatinib: A Third-Generation Inhibitor for the Treatment of CML. (2018) pubmed
- Olverembatinib in chronic myeloid leukemia-Review of historical development, current status, and future research. (2025) pubmed
- Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. (2018) pubmed